Canopus BioPharma Inc. is determined to ensure that, as a company, we are at the forefront of discoveries, developments and commercial breakthroughs within the pharmaceutical industry.
Canopus BioPharma comprises a unique and dynamic team focused on commercialising its three leading pharmaceutical products for the treatment of Hepatitis C, Mucositis and Influenza. We have an impressive pipeline of technologies forming a strong foundation for the future.
Canopus currently has two drug candidates in Phase IIa trials, both of which have outperformed the leading drug for their respective target disease indication in preclinical in vitro and animal studies. While Canopus will seek licensing partners for its pipeline technologies, as they progress through Phase II clinical trials.
Our current Business and Research & Development Plans build on our scientific achievements for disease indications such as Hepatitis C, Mucositis and Influenza. Canopus’ Hepatitis C technology is based upon a new family of pharmaceutical molecules, known as mogrosides. Our mucositis and cancer therapy technologies are built around the unique anti-angiogenesis and cell protection properties of the dithiolethione molecule, oltipraz. While our Influenza, broad spectrum drug exploits the antiviral properties of the well know and widely prescribed cholesterol lowering family of drugs, statins.
We, at Canopus BioPharma, strongly believe that the science in our pipeline will reach commercialization ensuring the commercial success of Canopus BioPharma far into the future. It is a great moment for my team and I to continue the expansion of Canopus, which, with our collective commitment will become a true leader and partner in the pharmaceutical and biotechnology industry.
Looking forward, I continue to be excited about the prospects for Canopus BioPharma, especially now that we plan on moving our stock to a reporting market, where the potential value of our technologies and pipeline will be more realistically reflected for our shareholders. We are proud of the progress we’ve made to date but we do not believe we have reached our maximum potential as yet. We will continue to work hard to see our science successful and commercialised. It is by forming co-development partnerships with other leaders in the industry that Canopus will maintain its growth. We believe that given the current clinical developments of our lead drug candidates that such partnerships can be cemented in the near future and Canopus can itself move to a reporting exchange.
Patrick T. Prendergast
Chairman, Chief Executive Officer, (Director)